Novartis stated that its first-quarter profit and sales rose: Net income rose from USD 1.67 billion to USD 2.03 billion and net sales from USD 11.5 billion to USD 12.7 billion. The growth was heavily boosted by the successful drugs Entresto (heart-failure drug) and Cosentyx (psoriasis drug).
The Swiss pharmaceutical giant’s China sales were also very successful and grew by 18 percent, but the company was less lucky in the US, where Sandox’s (generics and biosimilars unit of Novartis) sales dropped by 18 percent.
Please follow and like us:
